Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Novel anticoagulant antidotes prove their worth

Reversal agents from Portola and BMS and Boehringer shine in late-stage clinical trials

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo wins anti-PD1 race in Europe

Treatment given the EMA nod of approval for melanoma

National Institute for Health and Care Excellence NICE logo

NICE opens consultation on Gilead’s leukaemia drug

Comes after the Institute rejects the treatment in new draft guidance

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

Boehringer Ingelheim headquarters

NICE U-Turn on Boehringer oncology drug

England’s drug price watchdog now recommends Vargatef for lung cancer after price cut

Roche Basel Switzerland

Roche maintains dominance as leading cancer drugmaker

But the firm’s growth is stalling as pricing pressures hit sales

- PMLiVE

AZ and BMS earn ASCO plaudits

Both firms tout new combination therapies at the annual cancer congress in Chicago

Bristol-Myers Squibb (BMS) building

BMS melanoma combo impresses at ASCO

Increases survival in difficult to treat form of skin cancer

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

UK Life Sciences Strategy - one year on

Express Scripts pushes for pay-for-performance in cancer

States it is the only way to fund the growing cost of cancer care

- PMLiVE

Amgen’s immuno-oncology drug scores in skin cancer

Firm hoping its novel treatment will be on the market be the end of this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links